01—Abstract
Summary
Summary of the 10-K filed March 10, 2004. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported net sales of $613.7 milliona for fiscal 2003 (ended December 27, 2003), up 10.7% from $554.6 million in 2002, and operating income of $138.6 million, up 13.3%.
Net income was $80.2 millionb, or $1.64 per diluted share, compared with $50.1 million, or $1.06 per diluted share, in 2002. The filing attributes growth mainly to the Research Models and Services (RMS) segment, which generated 66.0% of net sales and grew 14.5%, with operating margin rising to 31.2% from 29.0%. The Development and Safety Testing (DST) segment represented 34.0% of net sales and grew 3.9%, but its operating margin fell to 13.3% from 17.0%, partly due to the closure of a contract manufacturing facility and weak early-2003 toxicology demand.
The company ended 2003 with cash and cash equivalents of $182.3 millionc, up from $122.5 million, and net cash provided by operating activities of $123.8 million. Total debt was $186.0 million, consisting mainly of $185.0 million of 3.5% senior convertible debentures due 2022. Shareholders' equity rose to $464.6 million.
Management stated that no material legal proceedings were pending, and that the company's revolving credit facility of $100.0 milliond was undrawn at year end. The filing also flags risks, including dependence on pharmaceutical and government research funding, contract terminability on short notice, international currency exposure (international revenues were 30.8% of net sales), and a possible IRS challenge to tax benefits from the 1999 recapitalization, which carried a deferred tax asset of $71.6 million at year end. Subsequent events include the January 2004 acquisition of River Valley Farms for approximately $17.3 million and a first-quarter 2004 European reorganization expected to produce a one-time non-cash charge of approximately $7.9 million.
02—Key points
Key Highlights
- Net sales of $613.7 million in 2003, up 10.7% from $554.6 million in 2002
- Operating income of $138.6 million, up 13.3%, with operating margin at 22.6% versus 22.0% in 2002
- Net income of $80.2 million, or $1.64 per diluted share, versus $50.1 million, or $1.06 per diluted share, in 2002
- RMS segment (66.0% of net sales) grew 14.5% with operating margin of 31.2%; DST segment (34.0% of net sales) grew 3.9% with operating margin down to 13.3% from 17.0%
- Cash and cash equivalents rose to $182.3 million; operating cash flow was $123.8 million
- Total debt of $186.0 million, primarily $185.0 million of 3.5% senior convertible debentures maturing in 2022; $100.0 million revolving credit facility undrawn at year end
- January 2004 acquisition of River Valley Farms (approximately $17.3 million) and a first-quarter 2004 European reorganization expected to result in a one-time non-cash charge of approximately $7.9 million
03—Questions
Frequently Asked Questions
What drove revenue growth in 2003?
The increase was driven mainly by the RMS segment, where net sales rose $51.2 million, or 14.5%, to $405.1 million. Favorable foreign currency translation contributed approximately 5.6% of that gain, and increased pricing and higher unit volume of specialty models and services also contributed. DST net sales rose $7.9 million, or 3.9%, largely due to 2002 acquisitions.
Why did DST operating margin decline?
The filing attributes the decline to lower demand for services that affected gross margins, a $3.7 million charge for writing down contract manufacturing assets, and a full year of amortization related to the 2002 acquisitions. Cost containment partly offset these effects. DST operating margin was 13.3% in 2003 compared with 17.0% in 2002, though it improved sequentially from 1.9% in the first quarter to 19.3% in the fourth quarter.
How exposed is the company to foreign currency and government funding?
International revenues were 30.8% of net sales in 2003, and the company does not hedge foreign currency risk because sales and costs at foreign operations are in local currency. A substantial part of RMS sales depends on academic and research customers whose funding is partly tied to government sources such as the NIH, and the filing notes that grant funding timing can cause fluctuations in sales.
What risks could affect the 1999 recapitalization tax benefit?
The filing states that the IRS may contend that the 2000 reorganization and liquidating distribution should be integrated with the 1999 recapitalization. If successful, the expected future tax benefits would not be available and the related deferred tax asset would have to be written off. The net deferred tax asset from the Section 338(h)(10) election was $71.6 million as of December 27, 2003.
04—Continue